Showing 2741-2750 of 4063 results for "".
- Caren Mason, CEO of Starr Surgical, Named to Top 50 Healthcare Technology CEOs Of 2020https://modernod.com/news/caren-mason-ceo-of-starr-surgical-named-to-top-50-healthcare-technology-ceos-of-2020/2477827/The Healthcare Technology Report announced The Top 50 Healthcare Technology CEOs of 2020. Data on each CEO’s professional background was gathered and they were assessed across several key areas, including breadth of leadership experience in the healthcare technology industry, level of exper
- Atia Vision Closes Second Tranche Of $20M In Series D Financinghttps://modernod.com/news/atia-vision-closes-second-tranche-of-20m-in-series-d-financing/2477793/Atia Vision, which is developing of a modular presbyopia-correcting accommodating IOL, announced the closing of its second tranche of a Series D $20M financing. The financing will be used to continue early clinical experience treating cataract patients and support ex
- RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259https://modernod.com/news/regenerx-joint-venture-announces-efficacy-results-of-neurotrophic-keratopathy-phase-3-clinical-trial-with-rgn-259/2477764/ReGenTree LLC, a US joint venture company owned by GtreeBNT Co. and RegeneRx Biopharmaceuticals, announced the results of a randomized, double masked, placebo-controlled phase 3 clinical trial (SEER-1) using RGN-259 for the treatment of neurotrophic keratopathy (NK).
- Prof. John M. Nolan Receives Heidelberg Engineering Xtreme Research Award 2020https://modernod.com/news/prof-john-m-nolan-receives-heidelberg-engineering-xtreme-research-award-2020/2477755/Prof. John M. Nolan, from the Nutrition Research Centre Ireland, School of Health Science, Waterford Institute of Technology (Ireland), is the recipient of the Heidelberg Engineering Xtreme Research Award 2020 for his research related to macular pigment for vision health and function, as well as
- Tearlab Acquired by Accelmed Partners for $25 Millionhttps://modernod.com/news/tearlab-acquired-by-accelmed-partners-for-25-million/2477742/Private equity firm Accelmed Partners II (AP-II) has agreed to acquire TearLab for $25 million. The payment, which will be made over two tranches, will result in TearLab delisting from the “over the counter” OTCQB mar
- FDA Issues Emergency Use Authorization for Potential COVID-19 Treatmenthttps://modernod.com/news/fda-issues-emergency-use-authorization-for-potential-covid-19-treatment/2477695/The FDA issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited i
- iSTAR Medical: Biocompatible MIGS Implant Shows Outstanding Efficacy in Glaucoma Patientshttps://modernod.com/news/istar-medical-biocompatible-migs-implant-shows-outstanding-efficacy-in-glaucoma-patients/2477668/iSTAR Medical announced positive results from two clinical trials of its micro-invasive glaucoma surgery (MIGS) implant MINIject. Both studies showed consistent reduction of IOP and reduced need for IOP-lowering medication in over 50 patients with open angle glauco
- Regenxbio Announces Additional Positive Long-Term and Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-long-term-and-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2477630/Regenxbio provided additional long-term data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). In the phase 1/2a trial of RGX-314, 42 patients with severe wet AMD requiring frequent anti-vascular endothelial growth factor (anti-VE
- Alimera Sciences Pre-Announces Expected Topline Revenue for Q1 2020 and Provides COVID-19 Business Updatehttps://modernod.com/news/alimera-sciences-pre-announces-expected-topline-revenue-for-q1-2020-and-provides-covid-19-business-update/2477586/Alimera Sciences announced topline revenue guidance for the quarter ending March 31, 2020. Alimera expects to report consolidated net revenue for the first quarter of 2020 exceeding $14 million, which compares to $12.9 million in the first quarter of 2019. Additionally, the company strengthened i
- Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated With COVID-19https://modernod.com/news/aerie-pharmaceuticals-provides-2020-company-and-guidance-update-associated-with-covid-19/2477559/Aerie Pharmaceuticals provided a business update associated with the impact of the COVID-19 pandemic on company operations. While Aerie volumes increased in the first-quarter of 2020 compared to the fourth-quarter of 2019 for both Rhopressa (netarsudil ophthalmic solution) 0.02% and Rockla